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March 12, 2013:1121–3however, there is no convincing evidence that low-dose statins
impair muscle function (4) or cause muscle-related adverse ef-
fectsmore frequently than placebo (as already reported in CO-
RONA), except, perhaps, for very rare cases of rhabdomyolysis
(5,6). Muscle-related adverse events are, however, clearly increased
with high-dose simvastatin treatment (7). An alternative explana-
tion is that statins might increase the perception of fatigue through
a central nervous system effect, but this possibility is less likely with
a hydrophilic agent such as rosuvastatin (8).
Although rosuvastatin led to worsening of fatigue in a small
roportion of older patients with systolic heart failure, the clinical
ignificance of this finding is uncertain.
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117–25.Letters to the Editor
Why Are We Still Using
Coronary Bare-Metal Stents?
In their paper, Singla et al. (1) describe accurately the dilemma
faced by cardiologists when confronted with a frequent occurrence
in which a potential conflict may arise between the need for
long-term dual antiplatelet therapy (DAPT) in recipients of
drug-eluting stents (DES) and common real-life situations such as
the need for noncardiac surgery.
Despite a wealth of data demonstrating the superiority of DES
versus bare metal stents (BMS) in all types of lesions/patients (2), a
significant proportion of patients still receive a BMS. One of the most
frequent reasons is that implanting a BMS allows a 1-month duration
of DAPT compared with a DES (6 to 12 months in the European
Society of Cardiology guidelines, 12 months in the American Heart
Association/American College of Cardiology guidelines) (3,4).
To elucidate why BMSs are still used today, we prospectively
collected data from 31 centers in Europe and Asia to identify the
main reason for implantation of BMS rather than DES in 744
consecutive percutaneous coronary interventions performed from
April to May 2012. Eight indications for using BMS were
identified: large vessel diameter, 241 (32.4%); ST-segment eleva-
tion myocardial infarction, 132 (17.7%); reimbursement/
regulatory/other reasons, 70 (9,4%); advanced age, 92 (12.4%);
concomitant oral anticoagulant treatment, 84 (11.3%); increased
bleeding risk, cancer, or anemia, 71 (9.5%); planned noncardiac
surgery within the next year, 41 (5.5%); and anticipated poor
DAPT compliance, 13 (1.7%).
This demonstrated that the use of a BMS was directly driven by
a concern about either bleeding or DAPT compliance in 301
(40.5%) cases. Although, as underlined by the authors, the risk of
stent thrombosis is at its highest when DAPT discontinuation
occurs during the first month after PCI, most interventions can be
postponed for 1 month, and the selection between BMS and DES
is then made in consideration of mid-term DAPT requirements (1
month only vs. 1 year).
This implies that a number of patients currently treated with a
BMS can be considered to have been deprived of a more efficacious
DES because of a concern about prolonged DAPT. Data have now
become available to support a 3- to 6-month course of DAPT after
DES implantation (5,6), but there is a real need for a device
combining the favorable effects of DES on restenosis and a DAPT
course of only 1 month when necessary.
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Reply
We thank Dr. Morice and colleagues for sharing their data
regarding reasons for implanting a bare metal stent (BMS) in
preference to a drug-eluting stent (DES). In their series, a BMS
was chosen because of the need for noncardiac surgery (NCS)
within the next year in 5.5% of patients, an incidence similar to
that reported in previous studies (1).We completely agree with the authors that a sizable percentage
of BMSs are implanted to avoid the risks associated with long-
term dual antiplatelet therapy (DAPT). We also agree with the
authors’ ideal DES, which would require only a limited period of
DAPT after implantation. It is important to emphasize, as we
noted in our paper (1), that the actual major adverse cardiac event
risk after NCS, a well-known prothrombotic stimulus, remains
uncertain, both during the highest risk period (0 to 6 weeks after
stent implantation) and thereafter. Further, the value of DAPT to
prevent ischemic events during NCS, in the traditional high-risk
period and beyond, also is uncertain, as is the relative increased
bleeding risk from DAPT continuation. As there is a large cohort
of stent patients undergoing NCS, determining the benefit–risk
ratio of maintaining DAPT during NCS in a scientifically rigorous
study is a laudable goal.
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